US Customs Laboratory Methods for THC (2000)

Name: US Customs Laboratory Methods for THC (2000)
Brand: The Richard Rose Report
SKU: 7893
Availability: InStock

11 pages. Cut-off = 1 ppm THC, which is why DEA’s 2001 Interpretive Rule legalizing all Hemp products meant “‘no THC’ = 1 ppm”, thus HIA v DEA 1 and 2 were unnecessary and an intentional mis-reading of DEA’s Interpretive Rule, greatly hurting the industry. Yes, HIA asked for DEA’s opinion on the legality of hemp products, after due deliberation DEA decided to legalize all hemp products, then HIA sued DEA for it.

Copyright 1994-2024 Richard Rose, all rights reserved. Any views expressed herein are the personal opinion of Richard Rose. This is a noncommercial public service. There are no warranties whatsoever as to the legality, suitability, ownership, purpose, or accuracy of this information. I am not a doctor or a lawyer. If you have medical questions, please seek a medical professional. If you have legal questions, please seek a legal professional. Information found here is not intended to diagnose, cure, treat, or prevent any disease. These statements and subsequent links found here have not been evaluated by the U.S. Food and Drug Administration (FDA). Hemp is not subject to international drug controls and is grown legally around the world. The information posted here is for educational purposes only and is not to be considered legal or medical advice, and is not intended to replace consultation with a qualified legal or medical professional. This website uses cookies. By continuing to use this service, you agree to their use. This is provided on an “as is,” “as available” basis without warranties of any kind, express or implied. The user assumes all responsibility and risk for the use of this website. Links are provided only as an informational resource, and it should not be implied that we own, recommend, endorse or approve of any of the content at the linked sites, nor are we responsible for their content. Unless otherwise stated, nobody pays us nuttin’ to post content, and we have no sponsors unlike NASCAR. By providing your email address to us you agree to be on the free The Richard Rose Report… This Week mailing list; you may unsubscribe at any time. There is no charge. To learn more about how we collect, keep, and process your private information in compliance with GDPR, please view our privacy policy via a link at the bottom of this page. Void where prohibited. Specifications subject to change without notice. If you don’t agree with the above please leave immediately. All patents, service marks, trademarks, and copyrights are the property of their respective owners. To the best of my knowledge, all Articles, Downloads, and Posts authored by RR are absolutely not written with any type of AI, just a human brain. Grammarly and autocorrect might be used to make minor edits. Posts authored under CannaSearch Daily are written by the original external poster, and no claim is made for those. It’s obvious that GPT language models will be deployed everywhere, but their accuracy is still low so I avoid them for now. Plus writers write.

Discrepancies between the stated contents and analytical findings for electronic cigarette liquid products: Identification of the new cannabinoid, Δ<sup>9</sup>-tetrahydrocannabihexol acetate July 23, 2024
A number of synthetic cannabinoids have been appearing in the recreational drug market for more than a decade. Recent additions are so-called semi-synthetic cannabinoids, and they structurally closely resemble the main psychoactive component of cannabis, Δ⁹-tetrahydrocannabinol. Knowledge of new (semi-)synthetic cannabinoids is essential to help identify them in authentic forensic case samples. Therefore, the aim […]
Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report July 23, 2024
Developmental Epileptic encephalopathies (DEEs) are severe neurological conditions where cognitive functions appear modulated by both seizure and interictal epileptiform activity. Cannabidiol (CBD) has been shown to be highly effective in the treatment of drug-resistant seizures in patients with DEEs. Along with its antiseizure effects, CBD demonstrated clinical beneficial effects in patients' quality of life, sleep […]
Medicinal cannabis tea contains variable doses of cannabinoids and no terpenes July 23, 2024
Tea is a recommended way of administration of prescribed cannabis plant products in Denmark. We aimed to investigate the cannabinoid and terpene doses contained in different teas. We analysed tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabidiolic acid (CBDA), and terpene concentrations in three repeated preparations of each type of tea, and in plant material. […]
Potency analysis of twelve cannabinoids in industrial hemp via ultrahigh-performance liquid chromatography-tandem mass spectrometry July 22, 2024
CONCLUSIONS: This study established a UHPLC-MS/MS method for the simultaneous and rapid quantitative determination of twelve cannabinoids in industrial hemp flowers and leaves in 11 min. The method was used to analyze 43 industrial hemp flower and leaf samples, with the data being statistically analyzed. Based on the statistical analysis of the cannabinoids, hemp from […]
Preventing new substance use behaviors in youth: evaluation of a two-year comprehensive program July 22, 2024
INTRODUCTION: The Avenir Santé Association implemented a comprehensive prevention program targeting the consumption of the emerging psychoactive substances ecstasy (MDMA), cannabidiol (CBD), and nitrous oxide (N(2)O).
Oral pre- and early postnatal cannabis exposure disinhibits ventral tegmental area dopamine neuron activity but does not influence cocaine preference in offspring in mice July 22, 2024
Cannabis consumption has increased from 1.5% to 2.5% in Canada between 2012 and 2019. Clinical studies have indicated effects of prenatal cannabis exposure on birth weight, substance use, and neurodevelopmental disorders, but are confounded by several difficult to control variables. Animal models allow for examination of the mechanism of cannabis-induced changes in neurodevelopment and behavior, […]
Elemental Profiling of Common Anti-diabetic Medicinal Plants of Swat and Peshawar Districts of Khyber Pakhtunkhwa (KPK) Province of Pakistan: An Investigation Using PIXE and ICP-OES July 22, 2024
The use of medicinal plants is integral to addressing liver, heart, lung, and other metabolic issues. These plants are rich in vitamins, minerals, flavonoids, and alkaloids, which collectively help in lowering intestinal glucose absorption and increasing insulin secretion by pancreatic tissues. Elemental analysis, encompassing major, minor, and trace elements, was performed on various parts (leaves, […]
Regulatory Framework for Cannabis: A Position Paper From the American College of Physicians July 22, 2024
Cannabis, also known as marijuana, is the dried flowers, stems, seeds, and leaves of the Cannabis sativa plant. It contains more than 100 compounds, including tetrahydrocannabinol, which has psychoactive effects. Federal law prohibits the possession, distribution, and use of cannabis outside limited research activities, but most states have legalized cannabis for medical or recreational use. […]
The reality of epilepsy in primary care in Rio de Janeiro: the importance of educational projects for better patient care July 22, 2024
CONCLUSION: There are deficits in the knowledge of UBS professionals in the management of epilepsy. Specialized training is imperative to optimize the care offered within SUS.
Batch and Continuous Flow Total Synthesis of Cannabidiol July 22, 2024
Herein, we present a comprehensive total synthesis of cannabidiol integrating both batch and continuous flow conditions. Our approach is planned to streamline the synthesis of olivetolic acid derivatives and utilize an enantiomerically pure monoterpene moiety obtained from naturally occurring (R)-(+)-limonene by photocatalysis. Key reactions, including the synthesis of olivetolic ester and a Friedel-Crafts alkylation, are […]
Association between cannabis use and nicotine use persistence among adolescents July 20, 2024
CONCLUSIONS: Adolescents who use cannabis may be at elevated risk for persistent nicotine use.
The anxiolytic effects of cannabinoids: A comprehensive review July 20, 2024
Cannabinoids, notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), have emerged as promising candidates for anxiety disorder treatment, supported by both preclinical and clinical evidence. CBD exhibits notable anxiolytic effects with a favourable safety profile, though concerns regarding mild side effects and drug interactions remain. Conversely, THC, the primary psychoactive compound, presents a range of side effects, […]
Modeling the liquid-liquid chromatography separation of cannabinoids from hemp extracts July 20, 2024
The separation of cannabinoids from hemp materials is nowadays one of the most promising industrial applications of liquid-liquid chromatography (LLC). Despite various experimental research efforts to purify cannabinoids, there are currently few works on process modeling. Thus, this study aimed to explore a straightforward approach to model the LLC separation of cannabinoids from two hemp […]
Cannabidiol: Pharmacodynamics and pharmacokinetic in the context of neuropsychiatric disorders July 19, 2024
In this chapter we explored the growing interest in cannabinoids, particularly cannabidiol (CBD), over the last two decades due to their potential therapeutic applications in neurodegenerative and psychiatric disorders. CBD, a major non-psychotomimetic compound derived from Cannabis sativa, is highlighted as a safer alternative to other cannabinoids like Δ9-tetrahydrocannabinol (THC). Clinical trials have been investigating […]
Cannabidiol and epilepsy July 19, 2024
Cannabidiol (CBD) has been investigated as a pharmacological approach for treating a myriad of neurological and psychiatric disorders, the most successful of them being its use as an antiseizure drug (ASD). Indeed, CBD has reached the clinics for the treatment of certain epileptic syndromes. This chapter aims to overview the pharmacology of CBD and its […]
Cannabidiol and Alzheimer's disease July 19, 2024
Alzheimer's disease (AD) stands as the most prevalent form of neuropsychiatric disorder among the elderly population, impacting a minimum of 50 million individuals worldwide. Current pharmacological treatments rely on the prescribing cholinesterase inhibitors and memantine. However,recently anecdotal findings based on low-quality real-world data had prompted physicians, patients, and their relatives to consider the use of […]
Cannabidiol in anxiety disorders: Current and future perspectives July 19, 2024
Anxiety disorders are highly prevalent psychiatric disorders, characterized by a chronic course and often accompanied by comorbid symptoms that impair functionality and decrease quality of life. Despite advances in basic and clinical research in our understanding of these disorders, currently available pharmacological options are associated with limited clinical benefits and side effects that frequently lead […]
Therapeutic potential of CBD in Autism Spectrum Disorder July 19, 2024
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by persistent deficits in social communication and interaction, as well as restricted and repetitive patterns of behavior. Despite extensive research, effective pharmacological interventions for ASD remain limited. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has potential therapeutic effects on several neurological and psychiatric […]
Therapeutic potential of cannabidiol in depression July 19, 2024
Major depressive disorder (MDD) is a widespread and debilitating condition affecting a significant portion of the global population. Traditional treatment for MDD has primarily involved drugs that increase brain monoamines by inhibiting their uptake or metabolism, which is the basis for the monoaminergic hypothesis of depression. However, these treatments are only partially effective, with many […]
Cannabidiol effects on fear processing and implications for PTSD: Evidence from rodent and human studies July 19, 2024
Cannabidiol (CBD) modulates aversive memory and its extinction, with potential implications for treating anxiety- and stress-related disorders. Here, we summarize and discuss scientific evidence showing that CBD administered after the acquisition (consolidation) and retrieval (reconsolidation) of fear memory attenuates it persistently in rats and mice. CBD also reduces fear expression and enhances fear extinction. These […]